Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial,Brendan M. Weiss,Saad Z. Usmani,Seema Singhal,Ajai Chari,Nizar J. Bahlis,Andrew Belch,Amrita Krishnan,Robert Vescio,Maria-Victoria Mateos,Amitabha Mazumder,Robert Z. Orlowski,Heather J. Sutherland,Joan Bladé,Emma C. Scott,Albert Oriol,Jesus G. Berdeja,Mecide Gharibo,Don A. Stevens,Richard Leblanc,Michael Sebag,Natalie S. Callander,Andrzej Jakubowiak,Darrell White,Javier de la Rubia,Paul G. Richardson,Steen Lisby,Huaibao Feng,Clarissa M. Uhlar,Imran Khan,Tahamtan Ahmadi,Peter M. Voorhees +31 more
Reads0
Chats0
TLDR
Daratumumab monotherapy showed encouraging efficacy in heavily pretreated and refractory patients with multiple myeloma, with a favourable safety profile in this population of patients.About:
This article is published in The Lancet.The article was published on 2016-04-09 and is currently open access. It has received 680 citations till now. The article focuses on the topics: Daratumumab & Population.read more
Citations
More filters
Journal ArticleDOI
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo,Asher Chanan-Khan,Katja Weisel,Ajay K. Nooka,Tamás Masszi,Meral Beksac,Ivan Spicka,Vania Hungria,Markus Munder,Maria-Victoria Mateos,Tomer M Mark,Ming Qi,Jordan M. Schecter,Himal Amin,Xiang Qin,William Deraedt,Tahamtan Ahmadi,Andrew Spencer,Pieter Sonneveld +18 more
TL;DR: Among patients with relapsed or relapsed and refractory multiple myeloma, daratumumab in combination with bortezomib and dexamethasone resulted in significantly longer progression-free survival than borteonib and DexamethAsone alone and was associated with infusion-related reactions and higher rates of thrombocytopenia and neutropenia.
Journal ArticleDOI
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
Meletios A. Dimopoulos,Albert Oriol,Hareth Nahi,Jesús F. San-Miguel,Nizar J. Bahlis,Saad Z. Usmani,Neil Rabin,Robert Z. Orlowski,Mieczysław Komarnicki,Kenshi Suzuki,Torben Plesner,Sung-Soo Yoon,Dina Ben Yehuda,Paul G. Richardson,Hartmut Goldschmidt,Hartmut Goldschmidt,Donna E. Reece,Steen Lisby,Nushmia Z. Khokhar,Lisa O'Rourke,Christopher Chiu,Xiang Qin,Mary E. Guckert,Tahamtan Ahmadi,Philippe Moreau +24 more
TL;DR: The addition of daratumumab to lenalidomide and dexamethasone significantly lengthened progression-free survival among patients with relapsed or refractory multiple myeloma.
Journal ArticleDOI
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje,Jesus G. Berdeja,Yi Lin,David S. Siegel,Sundar Jagannath,Deepu Madduri,Michaela Liedtke,Jacalyn Rosenblatt,Marcela V. Maus,Ashley Turka,Lyh Ping Lam,Richard A. Morgan,Kevin G. Friedman,Monica Massaro,Julie Wang,Greg Russotti,Zhihong Yang,Timothy B. Campbell,Kristen Hege,Fabio Petrocca,M. Travis Quigley,Nikhil C. Munshi,James N. Kochenderfer +22 more
TL;DR: The initial toxicity profile of a BCMA‐directed cellular immunotherapy for patients with relapsed or refractory multiple myeloma is reported andCAR T‐cell expansion was associated with responses, and CAR T cells persisted up to 1 year after the infusion.
Journal ArticleDOI
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal,Valérie Lauwers-Cances,Cyrille Hulin,Xavier Leleu,Denis Caillot,Martine Escoffre,Bertrand Arnulf,Margaret Macro,Karim Belhadj,Laurent Garderet,Murielle Roussel,Catherine Payen,Claire Mathiot,Jean Paul Fermand,Nathalie Meuleman,Sandrine Rollet,Michelle E. Maglio,Andrea A. Zeytoonjian,Edie Weller,Nikhil C. Munshi,Kenneth C. Anderson,Paul G. Richardson,Thierry Facon,Hervé Avet-Loiseau,Jean-Luc Harousseau,Philippe Moreau +25 more
TL;DR: Among adults with multiple myeloma, RVD therapy plus transplantation was associated with significantly longer progression‐free survival than RVD Therapy alone, but overall survival did not differ significantly between the two approaches.
Journal ArticleDOI
Proteasome inhibitors in cancer therapy
TL;DR: Investigation of the mechanisms of resistance is essential to further maximize the utility of this class of drugs in the era of personalized medicine.
References
More filters
Journal ArticleDOI
Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma
Torben Plesner,Hendrik-Tobias Arkenau,Henk M. Lokhorst,Peter Gimsing,Jakub Krejcik,Charlotte Lemech,Monique C. Minnema,Ulrik Lassen,Jacob P. Laubach,Tahamtan Ahmadi,Howard Yeh,Mary E. Guckert,Huaibao Feng,Nikolai Constantin Brun,Steen Lisby,Linda Basse,Antonio Palumbo,Paul G. Richardson +17 more
TL;DR: DARA+LEN+DEX has favorable safety profile with manageable toxicities in relapsed and RR MM, and the most frequent (>30% patients) adverse events (AEs) were neutropenia and diarrhea; no dose limiting toxicities (DLTs) were reported.
Journal ArticleDOI
CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon
TL;DR: Daratumumab is a human monoclonal antibody that has potent anti- Multiple Myeloma activity both as monotherapy and in combination with other multiple myeloma treatments, and has breakthrough designation on this basis.
Journal ArticleDOI
Daratumumab, a Human CD38 Antibody Induces Apoptosis of Myeloma Tumor Cells Via Fc Receptor-Mediated Crosslinking.
J. H. Marco Jansen,Peter Boross,Marije B. Overdijk,Jeroen J. Lammerts van Bueren,Paul W. H. I. Parren,Jeanette H. W. Leusen +5 more
TL;DR: In vitro data suggest that FcR-mediated crosslinking of DARA induces apoptosis of CD38 expressing tumor cells, and can thus be considered an additional mechanism of action for DARA.
Journal ArticleDOI
An Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma
Philippe Moreau,Maria-Victoria Mateos,Joan Bladé,Lotfi Benboubker,Javier de la Rubia,Thierry Facon,Raymond L. Comenzo,Joseph W. Fay,Xiang Qin,Tara Masterson,Jordan M. Schecter,Tahamtan Ahmadi,Jesús F. San Miguel +12 more
TL;DR: The aim of this ongoing open-label, 4-arm, multicenter, phase 1b study was to evaluate the safety, tolerability and dose regimen of DARA in combination with other MM backbone treatments.
Journal ArticleDOI
Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma.
TL;DR: This review focuses on the basic and clinical aspects of two emerging and promising novel MoAbs for MM, elotuzumab which targets CS1 and daratumumabWhich targets CD38, which are relatively specific to myeloma cells and expressed in more than 90% of MM patients.
Related Papers (5)
Targeting CD38 with daratumumab monotherapy in multiple myeloma
Henk M. Lokhorst,Torben Plesner,Jacob P. Laubach,Hareth Nahi,Peter Gimsing,Markus Hansson,Monique C. Minnema,Ulrik Lassen,Ulrik Lassen,Jakub Krejcik,Antonio Palumbo,Niels W.C.J. van de Donk,Tahamtan Ahmadi,Imran Khan,Clarissa M. Uhlar,Jianping Wang,A. Kate Sasser,Nedjad Losic,Steen Lisby,Linda Basse,Nikolai Constantin Brun,Paul G. Richardson +21 more
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
Meletios A. Dimopoulos,Albert Oriol,Hareth Nahi,Jesús F. San-Miguel,Nizar J. Bahlis,Saad Z. Usmani,Neil Rabin,Robert Z. Orlowski,Mieczysław Komarnicki,Kenshi Suzuki,Torben Plesner,Sung-Soo Yoon,Dina Ben Yehuda,Paul G. Richardson,Hartmut Goldschmidt,Hartmut Goldschmidt,Donna E. Reece,Steen Lisby,Nushmia Z. Khokhar,Lisa O'Rourke,Christopher Chiu,Xiang Qin,Mary E. Guckert,Tahamtan Ahmadi,Philippe Moreau +24 more
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Abstr Act,Sagar Lonial,Meletios A. Dimopoulos,Antonio Palumbo,Darrell White,Sebastian Grosicki,Ivan Spicka,Adam Walter‑Croneck,Philippe Moreau,Maria-Victoria Mateos,Hila Magen,Andrew Belch,Donna E. Reece,Meral Beksac,Andrew Spencer,Heather Oakervee,Robert Z. Orlowski,Masafumi Taniwaki,Christoph Röllig,Hermann Einsele,Ka Lung Wu,Anil K. Singhal,Jesús F. San Miguel,Morio Matsumoto,Jessica Katz,Eric Bleickardt,Valerie Poulart,Kenneth C. Anderson,Paul G. Richardson +28 more
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors
Michel de Weers,Yu-Tzu Tai,Michael S. van der Veer,Joost M. Bakker,Tom Vink,Daniëlle C H Jacobs,Lukas A. Oomen,Matthias Peipp,Thomas Valerius,Jerry W. Slootstra,Tuna Mutis,Wim K. Bleeker,Kenneth C. Anderson,Henk M. Lokhorst,Jan G. J. van de Winkel,Jan G. J. van de Winkel,Paul W. H. I. Parren +16 more